---
schema_version: "secwatch.filing_event.v1"
accession: "0001125345-25-000087"
form_type: "8-K"
ticker: "MGNX"
cik: "0001125345"
company_name: "MACROGENICS INC"
filed_at: "2025-06-10T23:59:59+00:00"
generated_at: "2026-05-19T15:09:34.044200+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# MacroGenics sells ZYNYZ royalty rights to Sagard for $70M; cash runway extended into H1 2027

## Summary
- Received $70M upfront from Sagard for capped royalty on global net sales of ZYNYZ (retifanlimab-dlwr).
- After Sagard collects $140M in royalties (2.0x), MacroGenics resumes all future royalty payments.
- MacroGenics retains other ZYNYZ economic interests, including development and commercial milestones.
- Cash, equivalents and securities were $154.1M at March 31, 2025; combined with $70M, runway now through first half 2027.
- ZYNYZ is a PD-1 inhibitor originally developed by MacroGenics and licensed to Incyte in 2017.

## SEC filing metadata
- accession: 0001125345-25-000087
- form_type: 8-K
- ticker: MGNX
- cik: 0001125345
- company_name: MACROGENICS INC
- filed_at: 2025-06-10T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1125345/000112534525000087/0001125345-25-000087-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1125345/000112534525000087/mgnx-20250609.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001125345-25-000087
- JSON: https://secwatch.observer/filing/0001125345-25-000087.json
- Plain text: https://secwatch.observer/filing/0001125345-25-000087.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.